Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
April 25, 2024 10:44 ET
|
Nexalin Technology, Inc.
HOUSTON, TEXAS, April 25, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced that the Company received notice from The Nasdaq Stock Market...
Nexalin Technology CEO Provides Letter to Shareholders
April 10, 2024 08:30 ET
|
Nexalin Technology, Inc.
HOUSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today provided the following letter to shareholders from the Company’s CEO,...
Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
April 09, 2024 08:30 ET
|
Nexalin Technology, Inc.
The new Gen-3 HALO™ Clarity 15 milliamp (mA) HOUSTON, TX, April 09, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced it...
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
April 04, 2024 13:00 ET
|
Nexalin Technology, Inc.
HOUSTON, TX, April 04, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office (USPTO)...
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
April 02, 2024 08:30 ET
|
Nexalin Technology, Inc.
HOUSTON, TEXAS, April 02, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the appointment of former Acting General Counsel to the...
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
March 28, 2024 08:30 ET
|
Nexalin Technology, Inc.
Collaborative Study involving the VA and UCSD achieved statistically significant decrease in PCS and PTSD symptoms versus control group The data supports the Company’s strategy to offer military...
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology
March 14, 2024 08:30 ET
|
Nexalin Technology, Inc.
HOUSTON, TEXAS, March 14, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that it has commenced sales of its second generation...
Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
March 13, 2024 08:30 ET
|
Nexalin Technology, Inc.
Event hosted by the U.S. Army Medical Research and Development Command’s (USAMRDC) Combat Casualty Care Research Program (CCCRP) Neurotrauma Portfolio and the Biomedical Advanced Research and...
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
March 06, 2024 08:30 ET
|
Nexalin Technology, Inc.
Clinical study demonstrated clinically meaningful and statistically significant improvements in key sleep parameters, compared to adult patients treated with placeboData published in...
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
February 08, 2024 08:30 ET
|
Nexalin Technology, Inc.
HOUSTON, TEXAS, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that its second generation (Gen-2), 15 milliamp (mA)...